


Status: Currently Official on 13-Feb-2025  
Official Date: Official as of 01-Oct-2024  
Document Type: USP Monographs  
DocId: GUID-C6AF8A22-A530-4F5C-924C-1E13D147F00C\_5\_en-US  
DOI: https://doi.org/10.31003/USPNF\_M938\_05\_01  
DOI Ref: rtm6g

© 2025 USPC  
Do not distribute

# Adenosine



$C_{10}H_{13}N_5O_4$  267.24  
6-Amino-9-β-D-ribofuranosyl-9H-purine;  
9-β-D-Ribofuranosyladenine CAS RN®: 58-61-7; UNII: K72T3FS567.

**DEFINITION**  
Adenosine contains NLT 98.0% and NMT 102.0% of adenosine ( $C_{10}H_{13}N_5O_4$ ), calculated on the dried basis.

**IDENTIFICATION**  
• **A.** [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), *Infrared Spectroscopy*: **197M**  
• **B.** The retention times of the major peaks of the *Sample solution* correspond to those of the *Standard solution*, as obtained in the Assay.

**ASSAY**

**Change to read:**

• **PROCEDURE**  
**Buffer:** 6.8 g/L of potassium hydrogen sulfate and 3.4 g/L of tetrabutylammonium hydrogen sulfate in a solution prepared as follows.  
Transfer suitable quantities of potassium hydrogen sulfate and ▲tetrabutylammonium▲ (ERR 1-Oct-2024) hydrogen sulfate to an appropriate volumetric flask, and dissolve in 90% of the flask volume of water. Adjust with 2 N potassium hydroxide to a pH of 6.5, and dilute with water to volume.

**Mobile phase:** Buffer and water (60:40)  
**System suitability solution:** 4 µg/mL each of [USP Adenine RS](#) and inosine in *Mobile phase*  
**Standard solution:** 0.2 mg/mL of [USP Adenosine RS](#) in *Mobile phase*  
**Sample solution:** 0.2 mg/mL of Adenosine in *Mobile phase*

**Chromatographic system**  
(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC  
**Detector:** UV 254 nm  
**Column:** 4.6-mm × 25-cm; 5-µm packing L1  
**Flow rate:** 1.5 mL/min  
**Injection volume:** 20 µL  
**Run time:** NLT 1.5 times the retention time of the adenosine peak

**System suitability**  
**Samples:** *System suitability solution* and *Standard solution*  
[NOTE—See [Table 1](#) for the relative retention times.]

**Suitability requirements**  
**Resolution:** NLT 1.5 between adenine and inosine, *System suitability solution*  
**Tailing factor:** NMT 2.0, *Standard solution*  
**Relative standard deviation:** NMT 0.7%, *Standard solution*

**Analysis**  
**Samples:** *Standard solution* and *Sample solution*  
Calculate the percentage of adenosine ( $C_{10}H_{13}N_5O_4$ ) in the portion of Adenosine taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_s$  = concentration of [USP Adenosine RS](#) in the *Standard solution* (mg/mL)

$C_u$  = concentration of Adenosine in the *Sample solution* (mg/mL)

**Acceptance criteria:** 98.0%–102.0% on the dried basis

#### IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

• **ORGANIC IMPURITIES**

**Buffer, Mobile phase, System suitability solution, and Chromatographic system:** Proceed as directed in the Assay.

**Standard solution:** 0.001 mg/mL of [USP Adenosine RS](#) in *Mobile phase*

**Sample solution:** 1 mg/mL of Adenosine in *Mobile phase*

#### System suitability

**Samples:** *System suitability solution* and *Standard solution*

[NOTE—See [Table 1](#) for the relative retention times.]

#### Suitability requirements

**Resolution:** NLT 1.5 between adenine and inosine, *System suitability solution*

**Relative standard deviation:** NMT 5%, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of each impurity in the portion of Adenosine taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times (1/F) \times 100$$

$r_u$  = peak response from the *Sample solution*

$r_s$  = peak response from the *Standard solution*

$C_s$  = concentration of [USP Adenosine RS](#) in the *Standard solution* (mg/mL)

$C_u$  = concentration of Adenosine in the *Sample solution* (mg/mL)

$F$  = relative response factor (see [Table 1](#))

**Acceptance criteria:** See [Table 1](#). Disregard peaks that are less than 0.05% of the adenosine peak.

**Table 1**

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Uridine <sup>a</sup>	0.29	0.73	0.10
Adenine	0.34	1.6	0.2
Inosine <sup>b</sup>	0.42	0.73	0.1
Guanosine <sup>c</sup>	0.51	0.86	0.10
Adenosine	1.0	—	—
Any individual unspecified impurity	—	1.0	0.10
Total impurities	—	—	0.5

<sup>a</sup> 1-β-D-Ribofuranosylpyrimidine-2,4(1H,3H)-dione.

<sup>b</sup> 9-β-D-Ribofuranosylpurine-6(1H)-one.

<sup>c</sup> 2-Amino-9-β-D-ribofuranosylpurine-6(1H)-one.

#### SPECIFIC TESTS

• [OPTICAL ROTATION, Specific Rotation \(781S\)](#): –68° to –72°

**Test solution:** 20 mg/mL in sodium hydroxide solution (1 in 20), determined on a sample previously dried at 105° for 2 h

• [LOSS ON DRYING \(731\)](#)

**Analysis:** Dry a sample at 105° for 2 h.  
**Acceptance criteria:** NMT 0.5%

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers, and store at controlled room temperature.
- **USP REFERENCE STANDARDS** (11).  
[USP Adenine RS](#)  
[USP Adenosine RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ADENOSINE	<a href="#">Documentary Standards Support</a>	SM52020 Small Molecules 5

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**  
Pharmacopeial Forum: Volume No. PF 38(6)

**Current DocID:** GUID-C6AF8A22-A530-4F5C-924C-1E13D147F00C\_5\_en-US  
**DOI:** [https://doi.org/10.31003/USPNF\\_M938\\_05\\_01](https://doi.org/10.31003/USPNF_M938_05_01)  
**DOI ref:** [rtm6g](#)

OFFICIAL